Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 10/2012

01-10-2012 | Breast Oncology

Disease Recurrence in Sentinel Node-Positive Breast Cancer Patients Forgoing Axillary Lymph Node Dissection

Authors: Amy Cyr, MD, Feng Gao, PhD, William E. Gillanders, MD, Rebecca L. Aft, MD, Timothy J. Eberlein, MD, Julie A. Margenthaler, MD, FACS

Published in: Annals of Surgical Oncology | Issue 10/2012

Login to get access

Abstract

Background

Clinically node-negative breast cancer patients usually undergo sentinel lymph node (SLN) biopsy. When metastasis is identified, completion axillary lymph node dissection (CALND) is recommended. Newer data suggest that CALND may be omitted in some women as it does not improve local control or survival.

Methods

Women with a positive SLN diagnosed between 1999 and 2010 were included in this review and were stratified according to whether they did or did not undergo CALND. Primary endpoints included recurrence and breast cancer-specific mortality. Differences between the groups and in time to recurrence were compared and summarized.

Results

Overall, 276 women were included: 206 (79 %) women who underwent CALND (group 1) and 70 (21 %) women in whom CALND was omitted (group 2). Group 1 patients were younger, had more SLN disease, and received more chemotherapy (P < 0.05 for each). The groups did not vary by tumor characteristics (P > 0.05 for each). Median follow-up was 69 (range 6–147) and 73 (range 15–134) months for groups 1 and 2, respectively. Five (2 %) women in group 1 and three (4 %) women in group 2 died of breast cancer (P = 0.39). Local–regional or distant recurrence occurred in 20 (10 %) group 1 patients and in 10 (14 %) group 2 patients (P = 0.39). On multivariate analysis, only estrogen receptor negativity and lymphovascular invasion predicted for recurrence.

Conclusions

Omission of CALND in women with SLN disease does not significantly impact in-breast, nodal, or distant recurrence or mortality. Longer-term follow-up is needed to verify that this remains true with time.
Literature
1.
Lyman GH, Giuliano AE, Somerfield MR, et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol. 2005;23:7703–20.PubMedCrossRef
2.
Cserni G, Gregori D, Merletti F, et al. Meta-analysis of non-sentinel node metastases associated with micrometastatic sentinel nodes in breast cancer. Br J Surg. 2004;91:1245–52.PubMedCrossRef
3.
Van Zee KJ, Manasseh DME, Bevilacqua JLB, et al. A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy. Ann Surg Oncol. 2003;10:1140–51.PubMedCrossRef
4.
Reed J, Rosman M, Verbanac KM, Mannie A, Cheng Z, Tafra L. Prognostic implications of isolated tumor cells and micrometastases in sentinel nodes of patients with invasive breast cancer: 10-year analysis of patients enrolled in the prospective East Carolina University/Anne Arundel Medical Center sentinel node multicenter study. J Am Coll Surg. 2009;208:333–40.PubMedCrossRef
5.
Chu KU, Turner RR, Hansen NM, Brennan MB, Bilchik A, Giuliano AE. Do all patients with sentinel node metastasis from breast carcinoma need complete axillary node dissection? Ann Surg. 1999;229:536–41.PubMedCrossRef
6.
Fant JS, Grant MD, Knox SM, Livingston SA, Ridl K, Jones RC, Kuhn JA. Preliminary outcome analysis in patients with breast cancer and a positive sentinel lymph node who declined axillary dissection. Ann Surg Oncol. 2003;10:126–30.PubMedCrossRef
7.
Grube BJ, Giuliano AE. Observation of the breast cancer patient with a tumor-positive sentinel node: Implications of the ACOSOG Z0011 trial. Semin Surg Oncol. 2001;20:230–7.PubMedCrossRef
8.
Hwang RF, Gonzalez-Angulo AN, Yi M, et al. Low locoregional failure rates in selected breast cancer patients with tumor-positive sentinel lymph nodes who do not undergo completion axillary dissection. Cancer. 2007;110:723–30.PubMedCrossRef
9.
Jeruss JS, Sener SF, Brinkmann EM, et al. Axillary recurrence after sentinel node biopsy. Ann Surg Oncol. 2005;12:34–40.PubMedCrossRef
10.
Naik AM, Fey JV, Gemignani M, et al. The risk of axillary relapse after sentinel lymph node biopsy for breast cancer is comparable with that of axillary lymph node dissection. Ann Surg. 2004;240:462–71.PubMedCrossRef
11.
Giuliano AE, McCall L, Beitsch P, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg. 2010;252:426–32.PubMed
12.
Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011;305:569–75.PubMedCrossRef
13.
Fisher B, Wolmark N, Bauer M, Redmond C, Gebhardt M. The accuracy of clinical nodal staging and of limited axillary dissection as a determinant of histologic nodal status in carcinoma of the breast. Surg Gynecol Obstet. 1981;152:765–72.PubMed
14.
Ragaz J, Jackson SM, Le N, et al. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Engl J Med. 1997;337:956–62.PubMedCrossRef
15.
Overgaard M, Hansen PS, Ovegaard J, et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med. 1997;337:949–55.PubMedCrossRef
16.
Quan ML, McCready D. The evolution of lymph node assessment in breast cancer. J Surg Oncol. 2009;99:194–8.PubMedCrossRef
17.
Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;366:1087–2106.
18.
Punglia RS, Morrow M, Winer EP, Harris JR. Local therapy and survival in breast cancer. N Engl J Med. 2007;356:2399–2405.PubMedCrossRef
19.
Sosa JA, Diener-West M, Gusez Y, et al. Association between extent of axillary lymph node dissection and survival in patients with stage I breast cancer. Ann Surg Oncol. 1998;5:140–9.PubMedCrossRef
20.
Hayward J, Caleffi M. The significance of local control in the primary treatment of breast cancer. Arch Surg. 1987;122:1244–7.PubMedCrossRef
21.
Bilimoria KY, Bentrem DJ, Hansen, NM, et al. Comparison of sentinel lymph node biopsy alone and completion axillary lymph node dissection for node-positive breast cancer. J Clin Oncol. 2009;27:2946–53.PubMedCrossRef
22.
23.
Pepels MJ, de Boer M, Bult P, et al. Regional recurrence in breast cancer patients with sentinel node micrometastases and isolated tumor cells. Ann Surg. 2012;255:116–21.PubMedCrossRef
24.
Chua B, Ung O, Boyages J. Treatment of the axilla in early breast cancer: past, present, and future. ANZ J Surg. 2001;71:729–36.PubMedCrossRef
25.
Albrecht MR, Zink K, Busch W, Ruhl U. Dissection or irradiation of the axilla in postmenopausal patients with breast cancer? Long-term results and long-term effects in 655 patients. Strahlenther Onkol. 2002;178:510–6.PubMedCrossRef
26.
Bansal M, Mohanti BK. Sentinel lymph node biopsy, axillary dissection and breast cancer: a radiation oncologist’s viewpoint. Natl Med J India. 2002;15:154–7.PubMed
27.
Yi M, Giordano SH, Meric-Bernstam F, et al. Trends in and outcomes from sentinel lymph node biopsy (SLNB) alone vs. SLNB with axillary lymph node dissection for node-positive breast cancer patients: experience from the SEER database. Ann Surg Oncol. 2010;17:343–51.PubMedCrossRef
28.
Milgrom S, Cody H, Tan L, et al. Characteristics and Outcomes of Sentinel Node-Positive Breast Cancer Patients after Total Mastectomy without Axillary-Specific Treatment. Ann Surg Oncol. 2012 [Epub ahead of print].
29.
Rayhanabad J, Yegiyants S, Putchakayala K, Haig P, Romero L, Difronzo LA. Axillary recurrence is low in patients with breast cancer who do not undergo completion axillary lymph node dissection for micrometastases in sentinel lymph nodes. Am Surg. 2010;76:1088–91.PubMed
30.
Yegiyants S, Romero LA, Haigh PI, DiFronzo LA. Completion axillary lymph node dissection not required for regional control in patients with breast cancer who have micrometastases in a sentinel node. Arch Surg. 2010;145:564–9.PubMedCrossRef
Metadata
Title
Disease Recurrence in Sentinel Node-Positive Breast Cancer Patients Forgoing Axillary Lymph Node Dissection
Authors
Amy Cyr, MD
Feng Gao, PhD
William E. Gillanders, MD
Rebecca L. Aft, MD
Timothy J. Eberlein, MD
Julie A. Margenthaler, MD, FACS
Publication date
01-10-2012
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 10/2012
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-012-2547-4

Other articles of this Issue 10/2012

Annals of Surgical Oncology 10/2012 Go to the issue

Breast Oncology

The Role for Sentinel Lymph Node Dissection after Neoadjuvant Chemotherapy in Patients who Present with Node-Positive Breast Cancer

Breast Oncology

Balancing Venous Thromboembolism and Hematoma After Breast Surgery

Breast Oncology

National Practice Patterns in Preoperative and Postoperative Antibiotic Prophylaxis in Breast Procedures Requiring Drains: Survey of the American Society of Breast Surgeons

Breast Oncology

Changing Behavior in Clinical Practice in Response to the ACOSOG Z0011 Trial: A Survey of the American Society of Breast Surgeons

Breast Oncology

American Society of Breast Surgeons Presidential Address: Could Quality Measures Impede Quality Care?

Breast Oncology

Reconstruction Patterns in a Single Institution Cohort of Women Undergoing Mastectomy for Breast Cancer